REDD1 is a determinant of low-dose metronomic doxorubicin-elicited endothelial cell dysfunction through downregulation of VEGFR-2/3 expressionMinsik Park, Young‐Myeong Kim|Experimental & Molecular Medicine|2021Cited by 16